← Evidence map

ArticleMolecular cancer therapeutics2024

Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer.

Sara G Danielli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2024
2025
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 38471796